Obesity News Source

Filters close
access_time Embargo lifts in 2 days
Embargo will expire: 10-Sep-2024 9:00 AM EDT Released to reporters: 5-Sep-2024 9:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 10-Sep-2024 9:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

3-Sep-2024 9:00 AM EDT
Pregnant women exposed to PFAS may be at risk for obesity, heart disease later in life
Endocrine Society

Women with higher levels of per- and polyfluoroalkyl substances (PFAS) during pregnancy may experience long-term weight gain and heart problems later in life, according to new research published in The Journal of Clinical Endocrinology & Metabolism.

Newswise: Ochsner Digital Medicine elevates program with a focus on total cardiometabolic health
Released: 4-Sep-2024 1:05 PM EDT
Ochsner Digital Medicine elevates program with a focus on total cardiometabolic health
Ochsner Health

Ochsner Digital Medicine is announcing an added capability to its cardiometabolic solution: comprehensive weight management care.

Released: 4-Sep-2024 8:55 AM EDT
Breaking the link between obesity and atrial fibrillation with a new cellular target
University of Illinois Chicago

Blocking oxidative stress enzyme prevents, even reverses, heart condition in lab models

access_time Embargo lifts in 2 days
Embargo will expire: 3-Sep-2024 11:00 AM EDT Released to reporters: 29-Aug-2024 11:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 3-Sep-2024 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Egg-White Rice – an Innovative Alternative Food Rich in Nutrients that Appeals to the Health Conscious
Released: 30-Aug-2024 8:55 AM EDT
Egg-White Rice – an Innovative Alternative Food Rich in Nutrients that Appeals to the Health Conscious
Chulalongkorn University

Chula Faculty of Allied Health Sciences has launched a ready-to-eat flourless rice innovation made from egg whites, branded as “eggyday”. This product is low in calories, filled with good-quality protein, high in calcium, complete with dietary fibers, and free of gluten.

Newswise: Nutrition know-how for patients taking anti-obesity medication
Released: 29-Aug-2024 1:05 PM EDT
Nutrition know-how for patients taking anti-obesity medication
UT Southwestern Medical Center

Since anti-obesity medications have become more widely known and prescribed, they have been touted as game-changing treatments for chronic overweight and obesity. But one common misconception about these medications is that they’re a magic bullet for better health, and it doesn’t necessarily matter what you eat when you’re taking them.

Released: 28-Aug-2024 12:30 PM EDT
Primary Care Providers Urged to Assist Patients Who Engage in Emotional Eating
Wolters Kluwer Health: Lippincott

Primary care providers are well positioned to address emotional eating because of their long-term relationships with patients, noted Jana DeSimone Wozniak, PhD and Hsiang Huang, MD, MPH, of Harvard Medical School and Cambridge Health Alliance in Cambridge, Massachusetts.

access_time Embargo lifts in 2 days
Embargo will expire: 26-Aug-2024 5:00 PM EDT Released to reporters: 20-Aug-2024 2:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 26-Aug-2024 5:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Five Common Myths About Weight Loss
Released: 26-Aug-2024 3:05 PM EDT
Five Common Myths About Weight Loss
University of Utah Health

Popular ideas about weight loss often aren’t based in science and can actively harm your health. Here are some of the most common myths, along with some tips to improve your health sustainably while maintaining a healthy attitude toward weight and food.

Released: 23-Aug-2024 12:05 PM EDT
Kids now see fewer TV ads for unhealthy food and drinks, but exposure remains high 
University of Illinois Chicago

University of Illinois Chicago study finds children are still exposed to over 1,000 ads a year for unhealthy foods

Released: 22-Aug-2024 7:05 AM EDT
First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
Palatin Technologies, Inc.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that patient dosing has started for the clinical study entitled: BMT-801: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity (ClinicalTrials.gov Identifier: NCT06565611).

Released: 21-Aug-2024 11:30 AM EDT
Reviews of Sweeteners’ Impact on Body Weight Focus on Different Studies and Produce Different Findings
Institute for the Advancement of Food and Nutrition Sciences

Published reviews of the impact of low- and no-calorie sweetener consumption on body weight differ because they are based on studies that ask different questions.

Released: 20-Aug-2024 7:00 AM EDT
Combining Two Diabetes Drugs Helps Promote Weight Loss and Blood Sugar Control
American Physiological Society (APS)

New research finds a combination of drugs improves weight loss, glucose control and insulin resistance better than either drug alone. Using two diabetes medications together, such as a semaglutide like Ozempic or Rybelsus, with a second, newer class of drug, may offer a noninvasive solution to help people with Type 2 diabetes lose weight and manage their condition without the need for bariatric surgery.

Newswise: ApoB test may be more accurate measure of heart disease risk
Released: 13-Aug-2024 10:05 AM EDT
ApoB test may be more accurate measure of heart disease risk
UT Southwestern Medical Center

The traditional lipid panel may not give the full picture of cholesterol-related heart disease risk for many Americans, according to a study led by UT Southwestern Medical Center researchers and published in JAMA Cardiology.

Released: 12-Aug-2024 10:05 AM EDT
Joslin Diabetes Center Investigator Rohit N. Kulkarni, MD, PhD, Awarded $10 Million NIH/NIDDK Grant for Pioneering Diabetes and Obesity Research
Beth Israel Lahey Health

Rohit N. Kulkarni, MD, PhD, the Diabetes Research and Wellness Foundation Endowed Chair and Co-Head of the Section on Islet & Regenerative Biology at Joslin Diabetes Center, has been awarded $9,920,607 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH).

Newswise: Brain Electrical Stimulation Suppresses Appetite. A New Frontier in Obesity Treatment?
Released: 12-Aug-2024 12:00 AM EDT
Brain Electrical Stimulation Suppresses Appetite. A New Frontier in Obesity Treatment?
National Research Council of Science and Technology

The team led by Dr. Shin of KERI has proposed a novel approach which is to suppress appetite by stimulating cerebral cortex electrically through scalp.

Newswise: Study identifies weight-loss drug target in the brain
Released: 8-Aug-2024 10:05 AM EDT
Study identifies weight-loss drug target in the brain
UT Southwestern Medical Center

A team led by researchers from UT Southwestern Medical Center and a university in South Korea has identified a subset of brain cells whose activation may be partially responsible for the effects of a popular class of weight loss drugs that includes semaglutide and tirzepatide. Their findings, published in Science, could eventually help scientists optimize the efficacy of these drugs, known as glucagon-like peptide-1 receptor agonists (GLP-1RAs).

Newswise: The Medical Minute: The truth about diabetes
Released: 7-Aug-2024 6:05 PM EDT
The Medical Minute: The truth about diabetes
Penn State Health

Type 1? Type 2? Do you have to take injections for the rest of your life? A Penn State Health expert discusses diabetes and how there are more options than ever to beat it.


  • Previous Page
  • Next Page

Showing results

11 of 1

close
1.05906